Inactive Instrument
Antibe Therapeutics Inc Stock Toronto S.E.
Stocks
ATE
CA0370251039
Biotechnology & Medical Research
OTC Markets Traded| 24-07-03 | Antibe Therapeutics : NOTICE TO CLAIMANTS OF ANTIBE THERAPEUTICS INC. (“ANTIBE”) | PU |
| 24-04-24 | Antibe Announces Appointment of Receiver | BU |
| 24-04-22 | ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS | AQ |
| 24-04-19 | Antibe Provides Update on CCAA Proceedings | BU |
| 24-04-16 | Antibe Announces TSX Delisting Review | BU |
| Manager | Title | Age | Since |
|---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 2015-11-30 |
David Vaughan
CTO | Chief Tech/Sci/R&D Officer | 76 | - |
| Investor Relations Contact | 50 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +4.17% | - | - | 11.47M | |
| +0.47% | +2.27% | +50.78% | +69.72% | 55.01B | |
| +2.83% | +0.04% | +38.07% | +82.59% | 54.24B | |
| +0.75% | +0.61% | -17.13% | -15.14% | 23.38B | |
| -0.45% | -2.52% | -1.00% | +370.60% | 22.57B | |
| +2.07% | +1.44% | +23.06% | -9.05% | 20.19B | |
| -2.15% | -2.30% | +27.27% | -33.01% | 17.86B | |
| -2.14% | -2.72% | +30.26% | +536.72% | 15.5B | |
| -3.14% | -8.09% | +160.68% | +292.18% | 14.2B | |
| -1.00% | +1.20% | +50.62% | +182.29% | 14.2B | |
| Average | -0.31% | -0.56% | +40.29% | +164.10% | 26.35B | |
| Weighted average by Cap. | +0.39% | -0.20% | +37.35% | +129.07% |
Employees
-
